
|Expert Interviews|April 18, 2022
Expert Interview: Pfizer/BioNTech Immune Response in Pediatric Clinical Trials
Author(s)Lois Levine, MA
Pfizer/BioNTech announce positive results for a third dose of their COVID-19 vaccine for children.
Advertisement
Grant Paulsen, MD, assistant professor, Division of Infectious Disease, Department of Pediatrics, Cincinnati Children's Hospital Medical Center in Ohio, and primary investigator for the hospital's clinical trial for a third dose (booster) for the Pfizer/BioNTech vaccine for COVID-19, discusses what the data might mean for children aged 5 to 11 years.
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
FDA Approves Enflonsia for the Prevention of RSV Lower Respiratory Tract Disease in Infants
2
Pharmacists Experience Challenges in Credentialing, Billing for Services | NCPA 2025
3
The Emergence of CGRP-Targeted Therapies is Transforming Migraine Care | NCPA 2025
4
FDA Approves Tezepelumab for as Add-On Treatment for Chronic Rhinosinusitis With Nasal Polyps
5